Seres Therapeutics, Inc. (MCRB)
NASDAQ: MCRB · Real-Time Price · USD
0.3700
-0.0299 (-7.48%)
Apr 17, 2025, 4:00 PM EDT - Market closed
Seres Therapeutics Stock Forecast
Stock Price Forecast
The 3 analysts with 12-month price forecasts for Seres Therapeutics stock have an average target of 4.00, with a low estimate of 0.75 and a high estimate of 10. The average target predicts an increase of 981.08% from the current stock price of 0.37.
Analyst Consensus: Hold
* Price targets were last updated on Mar 20, 2025.
Analyst Ratings
The average analyst rating for Seres Therapeutics stock from 5 stock analysts is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.
Recommendation Trends
| Rating | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Strong Sell | 0 | 0 | 0 | 0 | 1 | 1 |
| Total | 4 | 4 | 4 | 4 | 5 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Chardan Capital | Chardan Capital | Strong Buy Maintains $1.25 | Strong Buy | Maintains | $1.25 | +237.84% | Mar 20, 2025 |
| Goldman Sachs | Goldman Sachs | Strong Sell Maintains $1 → $0.75 | Strong Sell | Maintains | $1 → $0.75 | +102.70% | Mar 14, 2025 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $10 | Strong Buy | Maintains | $10 | +2,602.70% | Nov 14, 2024 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $1.25 | Strong Buy | Maintains | $1.25 | +237.84% | Nov 13, 2024 |
| JP Morgan | JP Morgan | Hold → Sell Downgrades n/a | Hold → Sell | Downgrades | n/a | n/a | Oct 24, 2024 |
Financial Forecast
Revenue This Year
18.74M
Revenue Next Year
n/a
from 18.74M
EPS This Year
-0.30
from 0.00
EPS Next Year
-0.33
from -0.30
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 77.2M | n/a | 131.3M | ||
| Avg | 18.7M | n/a | 42.5M | ||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 0.46 | -0.03 | 0.21 |
| Avg | -0.30 | -0.33 | 0.05 |
| Low | -0.56 | -0.62 | -0.07 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 52,700.0% | - | - |
| Avg | - | - | - |
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.